The Effect of Autologous Hematopoietic Stem Cell Transplantation on the Lower Urinary Tract Function Related to QoL in MS Patients

Inclusion Criteria: * Subjects (male and female) aged 18 and over * Subjects with signed informed consent * Subjects able to undergo examination according to the protocol * Patients indicated by neurologists to perform AHSCT or treated with the closest similar disease-modifying therapy (control group) Exclusion Criteria: * Subjects with a history of bladder cancer * Subjects after previous pelvic radiotherapy * Subjects with evidence of microscopic or macroscopic hematuria * Subjects with a history of bladder reconstruction (augmentation cystoplasty, catheterizable stoma), subjects after cystectomy * Treatment with botulinum toxin injection into the bladder wall in the last 12 months * Patients in whom the pharmacological treatment of the lower urinary tract has not been stable in the last 3 months and is being adjusted * Patients whose lower urinary tract symptoms are not stable for at least 3 months * Patients with a permanent catheter * Patients with recurrent symptomatic lower urinary tract infections - 3 or more episodes of infection in the last 12 months * Subjects with tubal urine screening-proven bacteriuria * Patients with acute lower urinary tract inflammation at baseline * Subjects with painful bladder syndrome * Patients after sacral neuromodulation * Patients with severe pelvic organ prolapse * Patients after radical pelvic surgery * Patients with a life expectancy of less than 5 years at the time of inclusion in the study * Lactating women, pregnant women, women trying to get pregnant, or sexually active women without a tendency to use safe contraception (hormonal-based oral contraceptives, injectable contraception, hormonally active implants, sexual abstinence, vasectomy in a partner) * Subjects who participated in another study in the previous 90 days